392 related articles for article (PubMed ID: 27296397)
1. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
Desai AS; Solomon S; Claggett B; McMurray JJ; Rouleau J; Swedberg K; Zile M; Lefkowitz M; Shi V; Packer M
Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296397
[TBL] [Abstract][Full Text] [Related]
2. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau J; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2013 Sep; 15(9):1062-73. PubMed ID: 23563576
[TBL] [Abstract][Full Text] [Related]
3. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz M; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2014 Jul; 16(7):817-25. PubMed ID: 24828035
[TBL] [Abstract][Full Text] [Related]
4. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
Mann DL; Greene SJ; Givertz MM; Vader JM; Starling RC; Ambrosy AP; Shah P; McNulty SE; Mahr C; Gupta D; Redfield MM; Lala A; Lewis GD; Mohammed SF; Gilotra NA; DeVore AD; Gorodeski EZ; Desvigne-Nickens P; Hernandez AF; Braunwald E;
JACC Heart Fail; 2020 Oct; 8(10):789-799. PubMed ID: 32641226
[TBL] [Abstract][Full Text] [Related]
5. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.
Yandrapalli S; Andries G; Biswas M; Khera S
Vasc Health Risk Manag; 2017; 13():369-382. PubMed ID: 29042791
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Kobalava Z; Kotovskaya Y; Averkov O; Pavlikova E; Moiseev V; Albrecht D; Chandra P; Ayalasomayajula S; Prescott MF; Pal P; Langenickel TH; Jordaan P; Rajman I
Cardiovasc Ther; 2016 Aug; 34(4):191-8. PubMed ID: 26990595
[TBL] [Abstract][Full Text] [Related]
7. Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.
UK HARP-III Collaborative Group
Nephrol Dial Transplant; 2017 Dec; 32(12):2043-2051. PubMed ID: 27646835
[TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors.
Norberg H; Bergdahl E; Lindmark K
Cardiovasc Ther; 2019; 2019():6745074. PubMed ID: 31772613
[TBL] [Abstract][Full Text] [Related]
9. Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice.
Liu Y; Fan Y; Li J; Chen M; Chen A; Yang D; Guan X; Cao Y
Biomed Pharmacother; 2021 Jan; 133():110824. PubMed ID: 33378988
[TBL] [Abstract][Full Text] [Related]
10. LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
Suematsu Y; Jing W; Nunes A; Kashyap ML; Khazaeli M; Vaziri ND; Moradi H
J Card Fail; 2018 Apr; 24(4):266-275. PubMed ID: 29325796
[TBL] [Abstract][Full Text] [Related]
11. The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects.
Langenickel TH; Tsubouchi C; Ayalasomayajula S; Pal P; Valentin MA; Hinder M; Jhee S; Gevorkyan H; Rajman I
Br J Clin Pharmacol; 2016 May; 81(5):878-90. PubMed ID: 26663387
[TBL] [Abstract][Full Text] [Related]
12. Postnatal Enalapril to Improve Cardiovascular Function Following Preterm Preeclampsia (PICk-UP):: A Randomized Double-Blind Placebo-Controlled Feasibility Trial.
Ormesher L; Higson S; Luckie M; Roberts SA; Glossop H; Trafford A; Cottrell E; Johnstone ED; Myers JE
Hypertension; 2020 Dec; 76(6):1828-1837. PubMed ID: 33012200
[TBL] [Abstract][Full Text] [Related]
13. Treatment optimization of angiotensin converting enzyme inhibitors and associated factors in Ayder Comprehensive Specialized Hospital: a cross-sectional study.
Atey TM; Teklay T; Asgedom SW; Mezgebe HB; Teklay G; Kahssay M
BMC Res Notes; 2018 Mar; 11(1):209. PubMed ID: 29592815
[TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle.
Mital S; Chung WK; Colan SD; Sleeper LA; Manlhiot C; Arrington CB; Cnota JF; Graham EM; Mitchell ME; Goldmuntz E; Li JS; Levine JC; Lee TM; Margossian R; Hsu DT;
Circulation; 2011 May; 123(21):2353-62. PubMed ID: 21576655
[TBL] [Abstract][Full Text] [Related]
15. The Mechanism of Action of LCZ696.
Menendez JT
Card Fail Rev; 2016 May; 2(1):40-46. PubMed ID: 28785451
[TBL] [Abstract][Full Text] [Related]
16. Influence of Age, Heart Failure and ACE Inhibitor Treatment on Plasma Renin Activity in Children: Insights from a Systematic Review and the European LENA Project.
Steichert M; Cawello W; Bajcetic M; Breur JMPJ; Dalinghaus M; Male C; de Wildt SN; Läer S;
Front Biosci (Landmark Ed); 2023 Dec; 28(12):335. PubMed ID: 38179766
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction.
Ishii M; Kaikita K; Sato K; Sueta D; Fujisue K; Arima Y; Oimatsu Y; Mitsuse T; Onoue Y; Araki S; Yamamuro M; Nakamura T; Izumiya Y; Yamamoto E; Kojima S; Kim-Mitsuyama S; Ogawa H; Tsujita K
JACC Basic Transl Sci; 2017 Dec; 2(6):655-668. PubMed ID: 30062181
[TBL] [Abstract][Full Text] [Related]
18. Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial.
Harrington J; Mentz RJ; Rockhold FW; Garg J; Butler J; De Pasquale CG; Ezekowitz JA; Lewis GD; O'Meara E; Ponikowski P; Troughton RW; Wong YW; Adamczyk R; Storie T; Blackman N; Hernandez AF
Circ Heart Fail; 2024 Feb; 17(2):e010676. PubMed ID: 38250799
[TBL] [Abstract][Full Text] [Related]
19. Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus.
Bahtiyar G; Gutterman D; Lebovitz H
Curr Diab Rep; 2016 Nov; 16(11):116. PubMed ID: 27730517
[TBL] [Abstract][Full Text] [Related]
20. LCZ696 Ameliorates Isoproterenol-Induced Acute Heart Failure in Rats by Activating the Nrf2 Signaling Pathway.
Hou M; Lu L; Wu X; Liu H
Appl Bionics Biomech; 2022; 2022():6077429. PubMed ID: 35528528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
